araag2/HINT huggingface dataset:
Clinical trial NCT02288208 (phase 1, status: terminated)
Conditions: hepatitis b
ICD codes: B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, B16.1
Drugs: antiviral therapy (tenofovir or entecavir), birinapant, placebo (for birinapant)
SMILES: CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(NC2=CC(F)=CC=C12)C1=C(C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)C2=CC=C(F)C=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    due to cranial nerve palsies observed
  
Eligibility criteria:

        Inclusion Criteria:

          -  Documented history of chronic Hepatitis B infection currently being treated with
             tenofovir or entecavir for at least 3 months

          -  Measurable titer of HBsAg

          -  HBV DNA level < 2 log copies/mL or 10² copies/mL

          -  No more than Child-Pugh score of 5 plus a valid FibroScan® of at least 10 readings
             with a median score of <7 and interquartile range of < 30%

          -  Adequate liver function, aspartate AST and ALT ≤2 x ULN

          -  Adequate renal function as evidenced by creatinine ≤2 mg/dL

        Exclusion Criteria:

          -  Participation in any interventional study within 4 weeks prior to Screening

          -  Known HIV infection, Hepatitis C, or other significant hepatic disorder including
             cirrhosis (Child-Pugh Class B or C)

          -  Serious illness or autoimmune disease or other known liver disease

          -  Uncontrolled hypertension

          -  Impaired cardiac function, uncontrolled cardiac arrhythmias despite medications, or
             clinically significant cardiac disease

          -  Currently breast feeding, pregnant or planning on becoming pregnant

          -  Known allergy or hypersensitivity to any of the formulation components of birinapant
             or placebo, including citric acid

          -  History of cranial nerve palsy

          -  Current treatment with anti-TNF therapies or has received treatment with anti-TNF
             therapies within the last 6 months

          -  Use of non-steroidal anti-inflammatory drugs
Clinical trial NCT02290340 (phase 1, status: completed)
Conditions: respiratory syncytial virus
ICD codes: J12.1, J20.5, J21.0, Z29.11, B97.4
Drugs: placebo, medi8897 10 mg, medi8897 25 mg, medi8897 50 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Healthy infants born between 32 weeks 0 days and 34 weeks 6 days gestational age

          -  Infants who are entering their first RSV season at the time of screening

        Key Exclusion Criteria:

          -  Gestational age < 32 weeks 0 days and >34 weeks 6 days

          -  Meets AAP or other local criteria to receive commercial palivizumab

          -  Any fever (≥ 100.4°F [≥ 38.0°C], regardless of route) or lower respiratory illness
             within 7 days prior to randomization

          -  Acute illness (defined as the presence of moderate or severe signs and symptoms) at
             the time of randomization

          -  Active RSV infection (a child with signs/symptoms of respiratory infection must have
             negative RSV testing) or known prior history of RSV infection

          -  Receipt of palivizumab or any RSV vaccine, including maternal RSV vaccination
Clinical trial NCT02299505 (phase 1, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: ceritinib
SMILES: CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1
Eligibility criteria:

        Inclusion:

          1. Histologically or cytologically confirmed diagnosis of stage IIIB (and is not a
             candidate for definitive multimodality therapy) or IV ALK-positive NSCLC.

          2. Patients may have received one prior treatment regimen with crizotinib (all other ALK
             inhibitors are excluded).

          3. Patients may have received prior chemotherapy, biologic therapy, or other
             investigational agents. ALK inhibitors other than crizotinib are excluded.

          4. Patient has a World Health Organization (WHO) performance status 0-2.

        Exclusion:

          1. Prior treatment with an ALK inhibitor other than crizotinib.

          2. History of carcinomatous meningitis.

          3. Presence or history of a malignant disease other than an ALK-positive advanced tumor
             that has been diagnosed and/or required therapy within the past 3 years.

        5. Clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6
        months) 6. Patient has history of interstitial lung disease or interstitial pneumonitis,
        including clinically significant radiation pneumonitis (i.e., affecting activities of daily
        living or requiring therapeutic intervention).

        7. Patient has other severe, acute, or chronic medical conditions 8. Patient is currently
        receiving treatment with warfarin sodium (Coumadin®) or any other coumarin-derivative
        anticoagulants.
Clinical trial NCT02300298 (phase 1, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: nintedanib, docetaxel
SMILES: COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion criteria:

          1. Patients aged 20 years or older at the date of informed consent

          2. Patients with body surface area (BSA)<1.5 m2 at screening

          3. Patients with histologically/cytologically confirmed locally advanced or metastatic
             adenocarcinoma subtype non-small cell lung cancer (NSCLC) after failure of first line
             platinum-based chemotherapy (patients with non-target lesion only are eligible) First
             line chemotherapy may include continuation or switch maintenance therapy. One prior
             adjuvant and/or neoadjuvant chemotherapy is accepted.

          4. Patients who have life expectancy of at least 3 months

          5. Patients who are Eastern Cooperative Oncology Group (ECOG) performance status (PS) of
             0 or 1 at screening

          6. Patients obtained written informed consent in accordance with International Conference
             on Harmonisation-Good Clinical Practice (ICH-GCP)and Japanese GCP

        Exclusion criteria:

          1. Patients who have received more than one prior line of chemotherapy (i.e., second or
             third line chemotherapy) for advanced or metastatic NSCLC (Prior monotherapies with an
             epidermal growth factor receptor tyrosine kinase inhibitors [EGFR-TKI]) or anaplastic
             lymphoma kinase (ALK) inhibitor can be allowed)

          2. Patients who have received previous therapy with other vascular endothelial growth
             factor (VEGF) or vascular endothelial growth factor receptor (VEGFR) inhibitors (other
             than bevacizumab) for the treatment of NSCLC at any time

          3. Patients who have received following treatments within 4 weeks prior to start of study
             therapy 1) Other investigational drugs 2) Chemo-, hormone-, immunotherapy, or
             monoclonal antibody.

          4. Patients who have received molecular target therapy including EGFR TKIs and ALK
             inhibitors within 2 weeks prior to start of study therapy

          5. Patents who have received radiotherapy within the past 3 months (in the case of
             limited -field [e.g. brain or bone metastasis] radiotherapy with palliative intent),
             within 2 weeks) prior to start of study therapy

          6. Patients who not recovered clinically relevant therapy related toxicities from
             previous chemotherapy and/or radiotherapy (=CTCAE grade 2 Adverse Event from previous
             treatment) at screening

        further exclusion criteria may be applied
Clinical trial NCT02300727 (phase 1/phase 2, status: terminated)
Conditions: mucositis
ICD codes: J34.81, K92.81, K12.30, K12.39, K12.33, N76.81, K12.31
Drugs: curcumin-mtd, mouthwash-standard pharmacy preparation, curcumin
SMILES: COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O, COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O
Reason stopped: 
    protocol failed to accrue sufficient subject to complete meaningful analysis.
  
Eligibility criteria:

        Inclusion Criteria:

          -  ≥ grade 2 oral mucositis related to chemotherapy for cancer

          -  Ability to understand and the willingness to review and sign a written informed
             consent document.

          -  ≥ 18 years of age

          -  Willingness to use adequate contraception prior to study entry, for the duration of
             study participation and for 30 days after the last dose for women of child-bearing
             potential and men

        Exclusion Criteria:

          -  Current use of therapeutic doses of anticoagulants such as warfarin or antiplatelet
             agents (prophylactic doses and agents are acceptable)

          -  Biliary tract obstruction or cholelithiasis

          -  History of gastric or duodenal ulcers or hyperacidity syndromes

          -  AST or ALT > 2 x ULN

          -  Total bilirubin ≥ 2 x ULN

          -  INR > 1.5

          -  Previous stem cell transplant (allogeneic or autologous)

          -  Preexisting oral disease, such as active oral infection, trauma to the oral mucosa or
             oral - ulceration prior to chemotherapy

          -  Known allergy/hypersensitivity to curcumin, yellow food coloring, or other members of
             the - Zingiberaceae (ginger) family

          -  Pregnant or breastfeeding
Clinical trial NCT02301104 (phase 1, status: completed)
Conditions: advanced solid tumors
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: tas-102
SMILES: ClC1=C(CN2CCCC2=N)NC(=O)NC1=O
Eligibility criteria:

        Inclusion

          1. Has provided written informed consent

          2. Has advanced solid tumors (excluding breast cancer)

          3. Has normal hepatic function, mild, moderate, or severe hepatic impairment

          4. ECOG performance status of ≤2

          5. Is able to take medications orally

          6. Has adequate organ function

          7. Women of childbearing potential must have a negative pregnancy test and must agree to
             adequate birth control if conception is possible. Males must agree to adequate birth
             control.

        Exclusion

          1. Certain serious illnesses or medical condition(s)

          2. Has had certain other recent treatment e.g. major surgery, anticancer therapy,
             extended field radiation, received investigational agent, shunt in the liver within
             the specified time frames prior to study drug administration

          3. Has received TAS-102

          4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any
             prior therapies

          5. Is a pregnant or lactating female
Clinical trial NCT02305563 (phase 1/phase 2, status: terminated)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: bms-936564, cytarabine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    business objectives have changed, slow accrual, the standard of care for the patient population
    changed and we were unable to accrue any longer.
  
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Newly Diagnosed Acute Myeloid Leukemia (AML)

          -  Considered inappropriate for intensive remission induction therapy by an investigator

          -  Not eligible for stem cell transplantation

        Exclusion Criteria:

          -  Acute promyelocytic leukemia

          -  Current Myelodysplastic syndrome only subjects

          -  Unstable angina or uncontrolled congestive heart failure

          -  Any other malignancy, excluding basal or squamous cell carcinoma of the skin, in situ
             melanoma, cervical carcinoma in situ, localized prostate cancer, or superficial
             bladder cancer stage 0, from which the subject has not been disease-free for at least
             3 years

          -  Respiratory disease requiring continuous supplemental oxygen

        Other protocol defined inclusion/exclusion criteria could apply
Clinical trial NCT02306291 (phase 1/phase 2, status: completed)
Conditions: leukemia, myeloid, acute
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: gmi-1271, mitoxantrone, etoposide, cytarabine, idarubicin
SMILES: OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O
Eligibility criteria:

        Inclusion criteria:

          1. AML (including secondary AML) diagnosed as per WHO criteria

          2. For relapsed/refractory subjects only:

               -  Subjects age ≥ 18 years with relapsed or refractory AML after ≤ 2 prior induction
                  regimens, at least one containing anthracyclines

               -  Medically eligible to receive MEC

               -  Absolute blast count (ABC) ≤ 40,000/mm

          3. For treatment-naïve subjects only:

               -  Subjects ≥ 60 years of age with newly diagnosed AML

               -  Medically eligible to receive "7+3" cytarabine/idarubicin

               -  ABC count ≤ 40,000/mm

          4. ECOG performance status 0-2

          5. Hemodynamically stable and adequate organ function

        Exclusion criteria:

          1. Acute promyelocytic leukemia

          2. Acute leukemia of ambiguous lineage (biphenotypic leukemia)

          3. Active signs or symptoms of CNS involvement by malignancy

          4. No prior G-CSF, GM-CSF or plerixafor within 14 days of study drug dosing

          5. Known history or evidence of active hepatitis A, B, or C or HIV

          6. Uncontrolled acute life threatening bacterial, viral or fungal infection

          7. Active graft versus host disease (GVHD) ≥ Grade 2 or extensive chronic GVHD requiring
             immunosuppressive therapy

          8. Hematopoietic stem cell transplantation ≤ 4 months of dosing

          9. Clinically significant cardiovascular disease
Clinical trial NCT02314299 (phase 1/phase 2, status: completed)
Conditions: diabetic macular edema, age-related macular degeneration
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513, H35.3130, H35.3230, H35.3110, H35.3120, H35.3131, H35.3132, H35.3190
Drugs: mtp-131
SMILES: CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  General:

               1. Adults aged ≥18 and ≤ 80 years

               2. Women of childbearing potential must have a negative urine pregnancy test at
                  Baseline and agree to use a highly effective method of contraception throughout
                  the study and 60 days after the last dose of study drug.

          -  DME Treatment Group:

               1. Central subfield thickness (CST) ≥325 microns as measured by spectral domain
                  optical coherence tomography (SD-OCT) at Screening and Baseline Visits

               2. BCVA (ETDRS) no better than 20/25 in the study eye

               3. BCVA (ETDRS) no worse than 20/640 in either eye

          -  AMD Treatment Group:

               1. Non-exudative, intermediate age-related macular degeneration defined as an eye(s)
                  having extensive intermediate drusen (10 or more drusen 63μm - 124μm) or large
                  drusen (1 or more ≥125 μm) with no evidence of advanced AMD (i.e., no choroidal
                  neovascularization or macular atrophy)

               2. BCVA (ETDRS) no worse than 20/400 in either eye

        Exclusion Criteria:

          -  General:

               1. Inability to self-administer eye drops

               2. Current use of or likely need for systemic medications known to be toxic to the
                  lens, retina or optic nerve (for example deferoxamine,
                  chloroquine/hydroxychloroquine [Plaquenil], tamoxifen, phenothiazines and
                  ethambutol)

               3. Any medical condition that, in the opinion of the investigator, would preclude
                  safe participation in the study or completion of all study requirements and
                  examinations

               4. Have a glycosylated hemoglobin (HbA1c) ≥ 12%

          -  Ocular Conditions:

               1. Any ocular condition in the study eye that in the opinion of the investigator
                  would prevent improvement in visual acuity or successful completion of any study
                  examination

               2. Ocular hypertension or glaucoma, dry eye, and any other ocular pathology in the
                  study eye requiring treatment with topical ophthalmic drops

                    -  Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT02316028 (phase 1/phase 2, status: completed)
Conditions: liver metastasis, colorectal cancer
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: decitabine
SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histological documentation of colorectal adenocarcinoma CRC stage IV with predominant
             unresectable liver metastases and at least one measurable metastatic liver lesion

          -  Performance status WHO criteria of < 2.

          -  Laboratory values: absolute neutrophil count (ANC) count > 1500 /mm³, Platelet count >
             100 000 /mm³, Lymphocytes > 800 /mm³, Serum creatinine < 2.0 mg/dl or creatinine
             clearance >40 ml/min, Serum bilirubin < 2.0 mg/dl

          -  Progressive disease following standard of care palliative systemic chemotherapy

          -  able to give written informed consent.

        Exclusion Criteria:

          -  No prior radiotherapy to all target liver lesions

          -  No previous history of gastric or hepatobiliary surgery (except for simple
             cholecystectomy, No concurrent liver disease or other serious medical disease or
             condition

          -  No concomitant use of other investigational drugs.

          -  No pre-existing neuropathy with a severity of > grade 1 in the WHO toxicity scale.

          -  No previous or concurrent malignancies except for adequately treated in situ carcinoma
             of the cervix uteri, basal or squamous cell carcinoma of the skin or any other
             malignancy given potentially curative treatment more than 5 years before study entry

          -  No pregnant or breast-feeding female patients, use of an effective contraceptive if
             the risk of conception exists during study treatment.

          -  No candidate for the resection of all CRC metastases with curative intent.
Clinical trial NCT02317471 (phase 1/phase 2, status: unknown status)
Conditions: gastric carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: oxaliplatin+s-1
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Disease characteristics: Histologically confirmed gastric carcinoma: clinical stage
             III (according to the Japanese gastric cancer classification), must have undergone
             radical resection

          2. Able to read and understand the informed consent document, must sign the informed
             consent

          3. Age: 18 to 75 years old

          4. Availability of at least 0.5 g tumor sample

          5. ECOG ≤1；life expectancy >=12 weeks, able to comply with study-related procedures

          6. Adequate bone marrow function including the absence of lymphopenia (ANC > 1,500/ mm3;
             Hemoglobin > 10g/dL ; platelet count >100,000/mm3), adequate liver function (serum
             glutamic oxaloacetic transaminase/ aspartate aminotransferase [AST], alanine amino
             transferase [ALT] <2.5 times institutional upper limit of normals [IULNs] and
             bilirubin (total) <1.5 times IULN), and adequate renal function (BUN and creatinine
             <1.5 times IULNs)

          7. Normal heart function

          8. NOT participate in ANY other clinical trials within 4 weeks prior to vaccination.

        Exclusion Criteria:

          1. Unable to get the informed consent

          2. Female patients who are pregnant or breastfeeding

          3. Progression prior to treatment as determined by the principal investigator

          4. Transplant recipient

          5. Patients currently diagnosed with Human Immunodeficiency Virus or other active
             uncontrolled infection

          6. Unstable or severe intercurrent medical conditions

          7. Patient with allergic constitution

          8. Patients with any systemic disease needed to be treated with immunosuppressant or
             Corticosteroids.
Clinical trial NCT02324673 (phase 1/phase 2, status: completed)
Conditions: seizures
ICD codes: G40.89, R56.1, F44.5, G40.501, G40.509, G40.111, G40.119
Drugs: cannabidiol oral solution
SMILES: CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Meets protocol-specified criteria for qualification and contraception, including
             treatment-resistant seizure disorder

          -  Is able to speak and understand the language in which the study is being conducted, is
             able to understand the procedures and study requirements and has voluntarily signed
             and dated an informed consent form approved by the Institutional Review Board before
             the conduct of any study procedure

          -  In the opinion of the Investigator, the participants and parent(s)/caregiver(s) are
             willing and able to comply with the study procedures and visit schedules, including
             venipuncture, inpatient stay at the study center, dosing at the study center twice a
             day as needed while an outpatient), and the Follow-up Visits (if applicable)

        Exclusion Criteria:

          -  Participant or parent(s)/caregiver(s) have daily commitments during the study duration
             that would interfere with attending all study visits

          -  History or current use of dietary supplements, drugs or over-the counter medications
             outside protocol-specified parameters

          -  Signs, symptoms or history of any condition that, per protocol or in the opinion of
             the investigator, might compromise:

               1. the safety or well-being of the participant or study staff

               2. the safety or well-being of the participant's offspring (such as through
                  pregnancy or breast-feeding)

               3. the analysis of results